Targeted Intracellular Delivery of Antisense Oligonucleotides via Conjugation with Small-Molecule Ligands

被引:110
作者
Nakagawa, Osamu [1 ]
Ming, Xin [1 ]
Huang, Leaf [1 ]
Juliano, Rudolph L. [1 ]
机构
[1] Univ N Carolina, Div Mol Pharmaceut, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA
关键词
BREAST-CANCER CELLS; SIRNA OLIGONUCLEOTIDES; STEALTH LIPOSOMES; POTENT CARRIER; PHARMACOLOGY; MECHANISMS; RECEPTORS; EFFICIENT; BARRIERS; BINDING;
D O I
10.1021/ja102635c
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Selective delivery of antisense or siRNA oligonucleotides to cells and tissues via receptor-mediated endocytosis is becoming an important approach for oligonucleotide-based pharmacology. In most cases receptor targeting has been attained using antibodies or peptide-type ligands. Thus, there are few examples of delivering oligonucleotides using the plethora of small-molecule receptor-specific ligands that currently exist. In this report we describe a facile approach to the generation of mono- and multivalent conjugates of oligonucleotides with small-molecule ligands. Using the sigma-receptor ligand anisamide as an example, we describe conversion of the ligand to a phosphoramidite and direct incorporation of this moiety into the oligonucleotide by solid-phase DNA synthesis. We generated mono- and trivalent conjugates of anisamide with a splice switching antisense oligonucleotide (SSO) and tested their ability to modify splicing of a reporter gene (luciferase) in tumor cells in culture. The trivalent anisamide-SSO conjugate displayed enhanced cellular uptake and was markedly more effective than an unconjugated SSO or the monovalent conjugate in modifying splicing of the reporter. Significant biological effects were attained in the sub-100 nM concentration range.
引用
收藏
页码:8848 / +
页数:3
相关论文
共 23 条
[1]   Cell-penetrating-peptide-based delivery of oligonucleotides: an overview [J].
Abes, R. ;
Arzumanov, A. A. ;
Moulton, H. M. ;
Abes, S. ;
Lvanciva, G. D. ;
Lversen, P. L. ;
Gait, M. J. ;
Lebleu, B. .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2007, 35 :775-779
[2]   Is a nitrogen atom an important pharmacophoric element in sigma ligand binding? [J].
Ablordeppey, SY ;
Fischer, JB ;
Glennon, RA .
BIOORGANIC & MEDICINAL CHEMISTRY, 2000, 8 (08) :2105-2111
[3]   Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis [J].
Alam, Md Rowshon ;
Dixit, Vidula ;
Kang, Hyunmin ;
Li, Zi-Bo ;
Chen, Xiaoyuan ;
Trejo, Joann ;
Fisher, Michael ;
Juliano, Rudy L. .
NUCLEIC ACIDS RESEARCH, 2008, 36 (08) :2764-2776
[4]   The Biological Effect of an Antisense Oligonucleotide Depends on Its Route of Endocytosis and Trafficking [J].
Alam, Md. Rowshon ;
Ming, Xin ;
Dixit, Vidula ;
Fisher, Michael ;
Chen, Xiaoyuan ;
Juliano, Rudolph L. .
OLIGONUCLEOTIDES, 2010, 20 (02) :103-109
[5]   Mining the receptorome [J].
Armbruster, BN ;
Roth, BL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (07) :5129-5132
[6]   Anisamide-targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cells [J].
Banerjee, R ;
Tyagi, P ;
Li, S ;
Huang, L .
INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (04) :693-700
[7]   RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform [J].
Bennett, C. Frank ;
Swayze, Eric E. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2010, 50 :259-293
[8]   Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-Peptide analogue of insulin-like growth factor 1 [J].
Cesarone, Gregory ;
Edupuganti, Om Prakash ;
Chen, Chang-Po ;
Wickstrom, Eric .
BIOCONJUGATE CHEMISTRY, 2007, 18 (06) :1831-1840
[9]   An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor [J].
Chono, Sumio ;
Li, Shyh-Dar ;
Conwell, Christine C. ;
Huang, Leaf .
JOURNAL OF CONTROLLED RELEASE, 2008, 131 (01) :64-69
[10]   Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands [J].
Cobos, E. J. ;
Entrena, J. M. ;
Nieto, F. R. ;
Cendan, C. M. ;
Del Pozo, E. .
CURRENT NEUROPHARMACOLOGY, 2008, 6 (04) :344-366